Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Rheumatoid Arthritis
Biotech
Lynk targets the JAK pot with phase 3 rheumatoid arthritis win
Lynk’s JAK1 trial hit its primary endpoint, boosting the prospects of a candidate designed to avoid the adverse events caused by existing drugs.
Nick Paul Taylor
Jan 12, 2026 8:45am
British biotech elevates with $70M and midstage arthritis asset
Oct 21, 2025 7:01pm
SetPoint nets $140M following FDA neuromod approval in RA
Aug 11, 2025 11:30am
AnaptysBio's PD-1 drug reduces rheumatoid arthritis in phase 2
Feb 12, 2025 9:57am
Lilly changes lead psoriasis program from $2.4B Dice buyout
Oct 30, 2024 10:00am
Fierce Biotech Bureau of Investigations seeks ACR poster burglar
Nov 16, 2023 12:59pm
